# AI for Pharma Competitive Intelligence — Map Drug Technology Landscapes & Patent Strategy > **Reviewed:** 2026-05-29 > **Canonical HTML:** https://bioskepsis.ai/use-cases/ai-for-competitive-intelligence-pharma > **Publisher:** BioSkepsis (EFEVRE TECH LTD, Larnaca, Cyprus) ## Goal Map the technology landscape, key players, patent strategies, and clinical-to-commercial translation gaps in a specific therapeutic area to inform R&D strategy, licensing decisions, or investment due diligence. Each step moves from the underlying science, to the competitive and patent map, to the hard question of whether the mechanistic claims actually hold up in humans. ## Built for pharma R&D strategy, licensing, and due diligence - **Pharma R&D strategists:** map a modality's science, key players, and white space before committing program resources. - **Business-development & licensing teams:** pressure-test a target platform's patent landscape and translational evidence ahead of a deal. - **Investment & due-diligence analysts:** separate marketed promise from peer-reviewed reality before a term sheet. ## The 6-step workflow — technology landscape to evidence-ranked strategies ### Step 1 — Enter a technology-focused research question covering mechanisms, formulations, and the commercial landscape Frame the question around a specific drug-delivery technology, therapeutic modality, or platform science. Ask about mechanisms of action, recent patents or formulation strategies, and the key players involved. **Example query** > "What are the current oral peptide delivery technologies, focusing on the mechanisms of absorption enhancers (such as SNAC and medium-chain fatty acids) and recent formulation patents (including strategies like pH modulation, enzyme inhibition, and nanotechnology-based carriers)?" ### Step 2 — Review the initial AI synthesis as a technology landscape overview BioSkepsis returns a structured answer covering the underlying science (e.g., how each absorption enhancer works at the molecular level), the marketed technologies (e.g., Rybelsus/SNAC, Mycapssa/C8, GIPET/C10), and the emerging approaches (e.g., nanocarriers, robotic pills). Check the **unverified citations panel** for flagged references before you rely on any single number. ### Step 3 — Map the competitive landscape: companies, platforms, and patent families Ask which companies and patent families dominate the space, and what citation clusters reveal about where innovation is converging. This produces a structured overview of key players, their proprietary platforms, and the emerging innovation hubs. **Example query** > "Which companies and patent families most frequently appear in oral peptide delivery filings, and what do citation clusters reveal about emerging innovation hubs or converging formulation strategies?" ### Step 4 — Assess the gap between mechanistic claims and clinical reality Ask how well the mechanistic claims in patents and preclinical studies hold up when tested in actual human pharmacokinetic studies. This is the critical "does it actually work?" question that separates hype from translational evidence. **Example query** > "How well do the mechanistic claims in oral peptide formulation patents (e.g., permeability enhancement, enzyme inhibition) align with observed pharmacokinetic outcomes in early clinical studies?" ### Step 5 — Identify recurring technical limitations and unresolved challenges Ask what limitations are repeatedly disclosed across patents, publications, and clinical reports. This surfaces the systemic barriers the field has not yet solved — the problems that any new entrant or investor must account for. **Example query** > "What are the key technical and clinical limitations repeatedly disclosed across oral peptide delivery patents and publications, such as variability in absorption, food effects, or dose dependency?" ### Step 6 — Benchmark formulation approaches by clinical evidence strength Ask which specific formulation strategies have the strongest clinical evidence for meaningful improvements — not just in bioavailability numbers, but in patient-relevant outcomes compared to existing therapies. **Example query** > "Which formulation approaches show the strongest evidence of clinically meaningful improvements in bioavailability or patient-relevant outcomes compared with injectable peptide therapies?" ## What you walk away with - **Technology landscape overview** — the underlying science, the marketed technologies, and the emerging approaches, with unverified citations flagged - **Competitive & patent map** — key players, proprietary platforms, recurring patent families, and the citation clusters that mark innovation hubs - **Claims-versus-reality assessment** — where patent and preclinical mechanistic claims hold up against human pharmacokinetic and clinical data - **Evidence-ranked strategies** — formulation approaches benchmarked by clinical-evidence strength and patient-relevant outcomes ## Try the live workflow Pre-loaded BioSkepsis session mapping the oral peptide delivery landscape: **https://app.bioskepsis.ai/research/use-case-ai-competitive-intelligence-pharma-r-d-oral/K55xSKzyWGtiayEG_Ohojw** ## Honest limits - **AI maps the published and patent literature — not confidential pipelines.** BioSkepsis cannot reveal unpublished filings, internal R&D, or undisclosed deal terms. - **Patent-family analysis is directional, not a freedom-to-operate opinion.** Use it to scope the landscape and brief counsel — get a formal FTO/patent search for licensing and clearance decisions. - **Citation flags surface likely errors, not certainty.** Verify each PMID and effect size against the source before it enters a due-diligence memo. - **Final strategic judgement is human.** BioSkepsis builds the evidence base; your team weighs commercial, regulatory, and IP risk. ## FAQ **What therapeutic areas and technologies does this competitive-intelligence workflow support?** Any drug-delivery technology, therapeutic modality, or platform science with a published and patent footprint — oral peptide delivery, mRNA/LNP platforms, antibody-drug conjugates, cell and gene therapy, small-molecule formulation science, and more. BioSkepsis draws on a 40M+ paper biomedical corpus including PubMed, bioRxiv, and medRxiv. **Can BioSkepsis analyse patent families directly?** BioSkepsis surfaces the companies, platforms, and patent families that recur across the published and patent literature, and reveals citation clusters that point to emerging innovation hubs. This is directional landscape intelligence — not a freedom-to-operate (FTO) opinion. **How does it separate marketing hype from real clinical evidence?** Steps 4 through 6 are built for exactly this. You ask how well mechanistic claims in patents and preclinical work hold up in human pharmacokinetic and clinical studies, which limitations recur, and which formulation strategies have the strongest clinical evidence for patient-relevant outcomes. **Is the output suitable for an investment due-diligence memo?** The output maps cleanly into the evidence sections of a due-diligence memo or licensing assessment. Final investment or deal decisions require your own commercial, regulatory, and legal review. **Does it cover preprints and clinical-trial literature, not just journals?** Yes. The corpus spans peer-reviewed journals, preprints (bioRxiv, medRxiv), pharmacology and pharmacokinetics, and clinical-trial reports. ## Related - [Use Case: AI for Drug Target Validation](/use-cases/ai-for-drug-target-validation) - [Use Case: AI for Literature Gap Analysis](/use-cases/ai-for-literature-gap-analysis) - [Use Case: AI for Drug Repurposing](/use-cases/ai-for-drug-repurposing) - [Feature: AI Literature Gap Finder](/features/literature-gap-finder) --- BioSkepsis is a product of EFEVRE TECH LTD (Larnaca, Cyprus). Third-party product, company, and regulatory agency names are referenced for identification only under the doctrine of nominative fair use.